Department of Research and Development, Elanco Animal Health, Greenfield, Indiana 46140, USA.
Ann N Y Acad Sci. 2010 Dec;1213:92-105. doi: 10.1111/j.1749-6632.2010.05788.x. Epub 2010 Oct 4.
The identification and early development of novel antimicrobial agents for use in veterinary medicine is subject to many of the same business and technical challenges as those found in antimicrobial agent use for human infectious disease. However, as awareness that some of the antimicrobial classes used in veterinary medicine are the same as used in human medicine, concern by multiple stakeholders has increased that this nonhuman use might be contributing to the problem of antimicrobial resistance to pathogens in humans, particularly with regard to food-borne diseases, such as salmonellosis and campylobacteriosis. Consequently, the interface between veterinary and human antibiotic use and resistance, especially with respect to human microbial food safety, has begun to redirect the industry pipeline of novel antimicrobial agents to be commercialized for use in veterinary medicine.
新型兽用抗菌药物的研发与人类传染病抗菌药物的研发面临着许多相同的商业和技术挑战。然而,人们逐渐意识到,一些在兽医中使用的抗菌药物与人类医学中使用的抗菌药物相同,多个利益相关者越来越担心这种非人类使用可能会导致人类病原体对抗菌药物的耐药性问题,特别是在食源性疾病方面,如沙门氏菌病和弯曲杆菌病。因此,兽医和人类抗生素使用和耐药性之间的界面,特别是人类微生物食品安全方面,已经开始重新引导新型抗菌药物的行业研发管道,以使其在兽医中商业化应用。